stoxline Quote Chart Rank Option Currency Glossary
Assembly Biosciences, Inc. (ASMB)
15.08  0.05 (0.33%)    05-24 16:00
Open: 14.88
High: 15.09
Volume: 2,250
Pre. Close: 15.03
Low: 14.88
Market Cap: 83(M)
Technical analysis
2024-05-24 4:51:15 PM
Short term     
Mid term     
Targets 6-month :  18.04 1-year :  21.07
Resists First :  15.44 Second :  18.04
Pivot price 14.07
Supports First :  13.31 Second :  12
MAs MA(5) :  15.01 MA(20) :  13.78
MA(100) :  12.53 MA(250) :  11.66
MACD MACD :  0.4 Signal :  0.3
%K %D K(14,3) :  84.2 D(3) :  85.8
RSI RSI(14): 63.3
52-week High :  20.04 Low :  7.67
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ ASMB ] has closed below upper band by 22.4%. Bollinger Bands are 56.4% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 4 days. This is a sign that the current trend might continue.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 15.1 - 15.17 15.17 - 15.25
Low: 14.7 - 14.78 14.78 - 14.86
Close: 14.95 - 15.08 15.08 - 15.2
Company Description

Assembly Biosciences, Inc., a clinical-stage biotechnology company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's lead product candidate is Vebicorvir, which as completed Phase 2 clinical trials to treat patients with chronic HBV infection. It is also developing ABI-H3733 that has completed Phase 1a clinical study, and ABI-4334, which is in pre-clinical trials for the treatment of HBV. The company has collaboration agreements with BeiGene, Ltd. and Arbutus Biopharma Corporation; and Antios Therapeutics, Inc. to evaluate a triple combination treatment in patients with chronic hepatitis B virus infection. It also has strategic license agreements with Indiana University Research and Technology Corporation; and Door Pharmaceuticals, LLC. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.

Headline News

Fri, 24 May 2024
Assembly Biosciences, Inc. (NASDAQ:ASMB) Director John G. Mchutchison Sells 2,117 Shares - MarketBeat

Fri, 24 May 2024
Assembly Biosciences executive sells over $2500 in stock - India

Thu, 23 May 2024
Assembly Biosciences Appoints Nicole S. White, PhD, as Senior Vice President of Pharmaceutical Development and ... - The Globe and Mail

Thu, 23 May 2024
Assembly Biosciences to Present During the SVB Leerink 11th Annual Global Healthcare Conference - The Globe and Mail

Tue, 21 May 2024
Assembly Biosciences (NASDAQ:ASMB) Stock Price Passes Above Two Hundred Day Moving Average of $11.40 - MarketBeat

Thu, 16 May 2024
Are Medical Stocks Lagging Entera Bio (ENTX) This Year? - Yahoo Canada Finance

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 5 (M)
Shares Float 4 (M)
Held by Insiders 33.2 (%)
Held by Institutions 13 (%)
Shares Short 31 (K)
Shares Short P.Month 60 (K)
Stock Financials
EPS -13.39
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 7.5
Profit Margin 0 %
Operating Margin -175.3 %
Return on Assets (ttm) -33.9 %
Return on Equity (ttm) -99 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 1.3
EBITDA (p.s.) -11.72
Qtrly Earnings Growth 0 %
Operating Cash Flow 23 (M)
Levered Free Cash Flow -8 (M)
Stock Valuations
PE Ratio -1.13
PEG Ratio -0.1
Price to Book value 2.01
Price to Sales 11.54
Price to Cash Flow 3.63
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android